Meeting Abstracts
Program and Abstracts from the Canadian Digestive Diseases Week 2016
Table 52
Contingency table for initial clinical decision made (without level knowledge), 6 month clinical outcomes (post-levels), and ITLs and FCPLs with hypothetical decision prompts%.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
A FCPL of <250 μg/g should prompt “no action" while a FCPL of ≥250 μg/g should prompt “action" (e.g., investigation, dose escalation etc.); ITLs <3.0 μg/mL should prompt “action - dose escalation”, ITLs 3.0–7.0 μg/mL should prompt “no action”, and ITLs >7.0 μg/mL should prompt “action – dose de-escalation.” Investigation refers to endoscopy. Dose de-escalation refers to the dose of IFX being decreased and/or decreasing the frequency of IFX dosing. Dose escalation refers to the dose of IFX being increased and/or increasing the frequency of IFX dosing. |